Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors inside the central nervous system, conolidine modulates alternate molecular targets. A Science Advances review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://raymondcbumf.affiliatblogger.com/89895485/not-known-factual-statements-about-alternative-natural-pain-relief-to-replace-traditional-painkillers